CN108473501B - 治疗化合物、其组合物及使用方法 - Google Patents

治疗化合物、其组合物及使用方法 Download PDF

Info

Publication number
CN108473501B
CN108473501B CN201780005254.4A CN201780005254A CN108473501B CN 108473501 B CN108473501 B CN 108473501B CN 201780005254 A CN201780005254 A CN 201780005254A CN 108473501 B CN108473501 B CN 108473501B
Authority
CN
China
Prior art keywords
group
alkyl
phenyl
compounds
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780005254.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473501A (zh
Inventor
P·吉伯恩斯
T·凯勒
M·扎克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN108473501A publication Critical patent/CN108473501A/zh
Application granted granted Critical
Publication of CN108473501B publication Critical patent/CN108473501B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CN201780005254.4A 2016-02-18 2017-02-17 治疗化合物、其组合物及使用方法 Expired - Fee Related CN108473501B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297061P 2016-02-18 2016-02-18
US62/297,061 2016-02-18
PCT/EP2017/053576 WO2017140825A1 (en) 2016-02-18 2017-02-17 Therapeutic compounds, compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN108473501A CN108473501A (zh) 2018-08-31
CN108473501B true CN108473501B (zh) 2021-07-16

Family

ID=58054137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780005254.4A Expired - Fee Related CN108473501B (zh) 2016-02-18 2017-02-17 治疗化合物、其组合物及使用方法

Country Status (5)

Country Link
US (2) US20180354959A1 (enExample)
EP (1) EP3416967B1 (enExample)
JP (1) JP6936236B2 (enExample)
CN (1) CN108473501B (enExample)
WO (1) WO2017140825A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400187T1 (it) 2014-11-06 2024-07-09 Bial R&D Investments S A Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
BR112018072552A8 (pt) * 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
CA3046435A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
JP2020510061A (ja) * 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
CR20190520A (es) 2017-05-22 2020-01-21 Hoffmann La Roche Composiciones y compuestos terapéuticos y métodos para utilizarlos
JP7228318B6 (ja) * 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
AU2020297415A1 (en) * 2019-06-18 2022-01-06 F. Hoffmann-La Roche Ag Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof
US20200399274A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482284A (zh) * 2009-07-02 2012-05-30 健泰科生物技术公司 作为jak抑制剂的吡唑并嘧啶化合物和方法
WO2014039595A1 (en) * 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2015068856A1 (en) * 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
WO2015177326A1 (en) * 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110033223A (ko) 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482284A (zh) * 2009-07-02 2012-05-30 健泰科生物技术公司 作为jak抑制剂的吡唑并嘧啶化合物和方法
WO2014039595A1 (en) * 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2015068856A1 (en) * 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
WO2015177326A1 (en) * 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Also Published As

Publication number Publication date
EP3416967B1 (en) 2022-02-09
US20210009599A1 (en) 2021-01-14
US20180354959A1 (en) 2018-12-13
WO2017140825A1 (en) 2017-08-24
JP2019505529A (ja) 2019-02-28
HK1259372A1 (zh) 2019-11-29
US11795170B2 (en) 2023-10-24
JP6936236B2 (ja) 2021-09-15
CN108473501A (zh) 2018-08-31
EP3416967A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
CN108473501B (zh) 治疗化合物、其组合物及使用方法
CN108368116B (zh) Janus激酶抑制剂、其组合物及用途
CN110785418A (zh) 作为irak4调节剂的异二氢吲哚酮衍生物
JP6900491B2 (ja) ピラゾロピリミジン化合物及びその使用方法
CN105745209A (zh) 三唑并吡啶化合物、组合物及其使用方法
CN110770229A (zh) 作为irak4调节剂的苯并呋喃化合物
US20230242530A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN110494434B (zh) 吡唑并氯苯基化合物、其组合物及其使用方法
US10189836B2 (en) Therapeutic compounds, compositions and methods of use thereof
CN107428750A (zh) 三唑并吡啶化合物及其使用方法
HK1259372B (zh) 治疗化合物、其组合物及使用方法
HK1258765B (en) Therapeutic compounds, compositions and methods of use thereof
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40009645B (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40009645A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40017827A (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
HK1258764B (en) Janus kinases inhibitors, compositions thereof and use thereof
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof
HK1245783A1 (en) Triazolopyridine compounds and methods of use thereof
HK1226720A1 (en) Triazolopyridine compounds, compositions and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259372

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210716